Ulcerative Colitis – Pipeline Review, H2 2017
- Pages: 433
- Published: October 2017
- Report Code: GMDHC9794IDB
Global Markets Direct’s, ‘Ulcerative Colitis – Pipeline Review, H2 2017’, provides an overview of the Ulcerative Colitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ulcerative Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis
The report reviews pipeline therapeutics for Ulcerative Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Ulcerative Colitis therapeutics and enlists all their major and minor projects
The report assesses Ulcerative Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Ulcerative Colitis
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4D Pharma PLC
AbbVie Inc
AbGenomics International Inc
Abivax SA
Adello Biologics LLC
Aerpio Therapeutics Inc
Akebia Therapeutics Inc
Allergan Plc
Am-Pharma BV
Amgen Inc
Aptevo Therapeutics Inc
Arena Pharmaceuticals Inc
Atlantic Bio Sci LLC
Atlantic Healthcare Plc
Blueberry Therapeutics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
Celltrion Inc
ChemoCentryx Inc
ChironWells GmbH
Coherus BioSciences Inc
Cosmo Pharmaceuticals NV
Dr. August Wolff GmbH & Co KG Arzneimittle
EA Pharma Co Ltd
Eli Lilly and Co
Enceladus Pharmaceuticals BV
Enterome Bioscience SA
Ferring International Center SA
Fresenius SE & Co KGaA
Galapagos NV
Genentech Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
iCo Therapeutics Inc.
Inception Sciences Inc
InDex Pharmaceuticals Holding AB
Innovate Biopharmaceuticals Inc
Intas Pharmaceuticals Ltd
Ironwood Pharmaceuticals Inc
Istesso Ltd
Johnson & Johnson
Kaken Pharmaceutical Co Ltd
Keystone Biologics Inc
Kyowa Hakko Kirin Co Ltd
LG Chem Ltd
LIPID THERAPEUTICS GmbH
Lycera Corp
Medestea Research & Production SpA
Merck & Co Inc
Miyarisan Pharmaceutical Company Ltd
Morphotek Inc
Ogeda SA
Oncobiologics Inc
OSE Immunotherapeutics
Pfizer Inc
Principia Biopharma Inc
Protab Ltd
Protagonist Therapeutics Inc
Protalix BioTherapeutics Inc
Qu Biologics Inc
Re-Pharm Ltd
Rebiotix Inc
RedHill Biopharma Ltd
Reliance Life Sciences Pvt Ltd
Sareum Holdings Plc
Seres Therapeutics Inc
Shire Plc
Sigmoid Pharma Ltd
Stelic Institute & Co Inc
Sterna biologicals Gmbh & Co KG
Synergy Pharmaceuticals Inc
Synlogic Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Thetis Pharmaceuticals LLC
Tillotts Pharma AG
TopiVert Ltd
TTY Biopharm Company Ltd
UCB SA
Ventria Bioscience
Vivelix Pharmaceuticals Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.